A Chinese phase 3 trial demonstrates the addition of the maintenance PARP-inhibitor niraparib following debulking surgery and first-line platinum chemo for ovarian cancer triples median progression-free survival from 8 to 24 months regardless of residual tumor burden or biomarker status. | Li, JAMA Oncol 2023
